The New York attorney general has begun an inquiry into Turing Pharmaceuticals, whose fiftyfold overnight increase in the price of a 62-year-old infection drug stoked a backlash against high pharmaceutical prices.
The attorney general’s office is looking not so much at the price increase itself but at whether Turing may have violated antitrust rules by restricting distribution of the drug, Daraprim, as a way to thwart generic competition, according to a letter sent by the attorney general’s office to Turing on Monday.
Read Full Article »